Lynn L. Silver

Statistics

Publications

Citations

10.2K

H-Index

Active since

1967

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

National Institutes of Health

University of Geneva

LEK Consulting (United States)

National Institute of Diabetes and Digestive and Kidney Diseases

Lynn L. Silver is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, microbiology, and antibiotic resistance.

ORCID

Publications per year

1967–2019

Publications

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 6.1K citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young et al. · Nature · 2006 · 815 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9

Outbreak of <i>Klebsiella pneumoniae</i> Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center

Neil Woodford, Philip M. Tierno, Katherine Young et al. · Antimicrobial Agents and Chemotherapy · 2004 · 446 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Antibacterial Agents That Inhibit Lipid A Biosynthesis

Hiroshi Ōnishi, Barbara A. Pelak, Lynn S. Gerckens et al. · Science · 1996 · 410 citations

Life Sciences, Microbiology, Pharmacology +15

Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding <scp>d</scp> -Ala- <scp>d</scp> -Ala

Min Ge, Zhong Chen, Harold Russell et al. · Science · 1999 · 320 citations

Life Sciences, Biochemistry, Pharmacology +17

1–5 of 42